MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
0.9561
+0.0655
+7.35%
Opening 10:48 03/14 EDT
OPEN
0.9000
PREV CLOSE
0.8906
HIGH
0.9994
LOW
0.8955
VOLUME
708.88K
TURNOVER
--
52 WEEK HIGH
2.640
52 WEEK LOW
0.6603
MARKET CAP
110.16M
P/E (TTM)
3.851
1D
5D
1M
3M
1Y
5Y
1D
Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Benzinga · 3d ago
Coherus BioSciences Reports 2024 Financial Growth
TipRanks · 3d ago
Coherus Biosciences, Inc. Q4 Loss Narrows
NASDAQ · 3d ago
*Coherus BioSciences 4Q Adj Loss/Shr 28c >CHRS
Dow Jones · 3d ago
*Coherus BioSciences: About 50 Employees Associated With UDENYCA Expected to Transfer to Accord BioPharma >CHRS
Dow Jones · 3d ago
Coherus Biosciences reports Q4 EPS (28c), consensus (13c)
TipRanks · 3d ago
*Coherus BioSciences: Post Divestiture Expected Cash of About $250 M, With Cash Runway Exceeding 2 Years >CHRS
Dow Jones · 3d ago
More
About CHRS
More
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
Recently
Symbol
Price
%Change

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.